Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This study was designed to determine how effective and safe a new investigational drug,
lapatinib, is in treating patients with treatment refractory or relapsed inflammatory breast
cancer. Tumor tissue collected pre-treatment and at Day 28 will be examined for biologic
activity by IHC (immunohistochemistry). Treatment will consist of daily oral therapy with
lapatinib. A patient may continue treatment as long as they are receiving benefit. Blood
samples for hematology and chemistry panels, MUGA/ECHO (multigated
acquisition/echocardiogram) exams and physical exams will be performed throughout the study
to monitor safety.